Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE In our study, we used trebananib, an angiopoietin 1/2 inhibitor and a novel small molecule MET kinase inhibitor in patient derived xenograft (PDX) models of ccRCC. 31582532 2020
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE Other tyrosine kinases' pathways, including PDGFR, Axl or MET have emerged as key signaling pathways involved in RCC biology. 30999623 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE Combination strategies of VEGF and MET inhibitors could lead to sustained and deep responses even in non-MET driven RCC by inhibiting pathways of VEGF resistance. 31554440 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE Cabozantinib is a potent inhibitor of VEGF, AXL and MET receptors providing rationale for its use in RCC. 31184937 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 GeneticVariation disease BEFREE Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology. 30017898 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE The significance of ligand-dependent MET activation in RCC bone metastasis is considered, and HAI-2 may be an important regulator in this system. 29890660 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 GeneticVariation disease BEFREE Likewise, papillary RCC has also been studied at the molecular level, which has shown a high level of mutations in the MET gene; early clinical data suggest the utility of MET targeted therapy. 30478013 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 AlteredExpression disease BEFREE C-Met protein levels were increased in 8 of 10 RCC tissue samples compared with their adjacent normal tissue and c-Met expression levels were positively associated with a high nuclear grade (P = 0.008) and pT stage (P = 0.002). 28427859 2017
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 AlteredExpression disease BEFREE We report here two pediatric patients with recurrent metastatic RCC whose tumors expressed MET and were treated with cabozantinib. 28417541 2017
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 GeneticVariation disease BEFREE For this purpose, tumor samples were analyzed for c-MET expression by immunohistochemistry (IHC), for c-MET copy number alterations by fluorescence in situ hybridization (FISH), and for c-MET mutations by next generation sequencing (NGS) in a retrospective cohort of 90 primary ccRCC of patients with metastases treated by first-line sunitinib. 28550387 2017
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor receptor as a promising target for RCC therapeutic agents.We have examined MET expression, frequency of MET gene copy gains and MET gene mutation in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.Out of a total of 572 clear-cell RCC, only 17% were negative for MET expression whereas 32% showed high protein levels. 27894094 2017
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE In the present study, tissue microarrays containing sunitinib-treated and untreated RCC tissues were stained with MET and AXL antibodies. 26364599 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE Renal cell carcinoma (RCC) is a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing (VHL/HIF pathway alterations and the subsequent up-regulation of HIF-responsive genes such as VEGF, PDGF, EGF, and glucose transporters GLUT1 and GLUT4, which justify the RCC reliance on aerobic glycolysis), energy sensing (fumarate hydratase-deficient, succinate dehydrogenase-deficient RCC, mutations of HGF/MET pathway resulting in the metabolic Warburg shift marked by RCC increased dependence on aerobic glycolysis and the pentose phosphate shunt, augmented lipogenesis, and reduced AMPK and Krebs cycle activity) and/or nutrient sensing cascade (deregulation of AMPK-TSC1/2-mTOR and PI3K-Akt-mTOR pathways). 27453294 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 GeneticVariation disease BEFREE The exonic MET variant rs11762213 is an independent predictor of adverse CSS and TTR in ccRCC and should be integrated into clinical practice for prognostic stratification. 26505625 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient. 26951228 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease CTD_human Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. 25401301 2015
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 AlteredExpression disease BEFREE Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis. 25186085 2015
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma. 24767687 2014
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 GeneticVariation disease BEFREE Subsequent sequence analysis revealed a heterozygous R988C mutation of the MET gene and a VHL deletion in both the primary tumor and the tumor-derived ccRCC cell line. 24929890 2014
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE Investigation of rare familial forms of renal cell carcinoma (RCC) has led to the identification of genes such as VHL and MET that are also implicated in the pathogenesis of sporadic RCC. 24000165 2013
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma. 23219378 2013
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 GeneticVariation disease BEFREE Germline mutations in the MET and fumarate hydratase (FH) genes lead to the development of type 1 and type 2 papillary RCCs, respectively, and such mutations of either the TSC1 or TSC2 gene increase the risk of RCC. 21228928 2010
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 GeneticVariation disease BEFREE Mutations of MET also have been identified in a subset of tumors from patients with sporadic type 1 papillary renal cell carcinoma (RCC). 19402075 2009
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 Biomarker disease BEFREE Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. 16914575 2006
Conventional (Clear Cell) Renal Cell Carcinoma
0.600 PosttranslationalModification disease BEFREE Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. 16585196 2006